KRAS and colorectal carcinoma: Remarkably, decreased phospho-MEK, phospho-ERK, phospho-BRAF, and phospho-CRAF were noted when both drugs were used in the treatment [45], all of which are known to be key molecules for EGFR resistance in mutant KRAS human CRC cells expressing SVCT-2.